Study With [225Ac]Ac-FL-020 in mCRPC Participants

计划入组 50 人 · 首次发布于 2024 年 7 月 9 日

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

计划入组 208 人 · 首次发布于 2013 年 4 月 18 日

A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens

计划入组 36 人 · 首次发布于 2024 年 12 月 13 日

[225Ac]Ac-macropa-nimotuzumab

[225Ac]Ac-DOTATATE

[225Ac]Ac-SSO110

AC Immune

Switzerland

Enlaces Academicos Internac Ac

Mexico

AC NEWCO PTY LTD

Australia

Novel Actinium-225 Radioconjugate Shows Promise Against Treatment-Resistant HER2-Positive Breast Cancer

FDA Clears IND for Full-Life's Actinium-225 c-MET Radioconjugate [225Ac]Ac-FL-261 in Non-Squamous NSCLC

HER2-Targeted Therapies Solidify Role in Early-Stage HER2-Positive Breast Cancer Treatment